Log in

NASDAQ:CBLICleveland BioLabs Competitors & Alternatives

$2.24
0.00 (0.00 %)
(As of 07/3/2020 04:00 PM ET)
Add
Compare
Today's Range
$2.21
Now: $2.24
$2.42
50-Day Range
$1.52
MA: $2.02
$4.26
52-Week Range
$0.50
Now: $2.24
$5.00
Volume525,800 shs
Average Volume3.52 million shs
Market Capitalization$25.54 million
P/E RatioN/A
Dividend YieldN/A
Beta0.95

Competitors

Cleveland BioLabs (NASDAQ:CBLI) Vs. IQV, INCY, EXAS, PPD, ICLR, and CRL

Should you be buying CBLI stock or one of its competitors? Companies in the industry of "commercial physical research" are considered alternatives and competitors to Cleveland BioLabs, including Iqvia (IQV), Incyte (INCY), EXACT Sciences (EXAS), PPD (PPD), Icon (ICLR), and Charles River Laboratories Intl. (CRL).

Cleveland BioLabs (NASDAQ:CBLI) and Iqvia (NYSE:IQV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Iqvia, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
Iqvia001503.00

Iqvia has a consensus price target of $153.7333, indicating a potential upside of 8.63%. Given Iqvia's higher probable upside, analysts clearly believe Iqvia is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 88.6% of Iqvia shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 6.0% of Iqvia shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Iqvia's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-220.62%-169.32%-102.29%
Iqvia1.93%18.48%5.05%

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Iqvia has a beta of 1.32, indicating that its share price is 32% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Iqvia's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million23.01$-2,650,000.00N/AN/A
Iqvia$11.09 billion2.44$191 million$5.9423.82

Iqvia has higher revenue and earnings than Cleveland BioLabs.

Summary

Iqvia beats Cleveland BioLabs on 10 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Incyte (NASDAQ:INCY) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Incyte, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
Incyte0101302.57

Incyte has a consensus price target of $100.65, indicating a potential downside of 5.47%. Given Incyte's higher probable upside, analysts clearly believe Incyte is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 91.3% of Incyte shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 16.1% of Incyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Incyte's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-220.62%-169.32%-102.29%
Incyte-16.87%-12.81%-9.55%

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Incyte has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Incyte's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million23.01$-2,650,000.00N/AN/A
Incyte$2.16 billion10.72$446.91 million$2.2347.74

Incyte has higher revenue and earnings than Cleveland BioLabs.

Summary

Incyte beats Cleveland BioLabs on 10 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and EXACT Sciences (NASDAQ:EXAS) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and EXACT Sciences, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
EXACT Sciences001603.00

EXACT Sciences has a consensus price target of $107.3333, indicating a potential upside of 23.86%. Given EXACT Sciences' higher probable upside, analysts clearly believe EXACT Sciences is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 86.9% of EXACT Sciences shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 1.8% of EXACT Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and EXACT Sciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-220.62%-169.32%-102.29%
EXACT Sciences-10.04%-13.98%-7.70%

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, EXACT Sciences has a beta of 1.89, indicating that its share price is 89% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and EXACT Sciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million23.01$-2,650,000.00N/AN/A
EXACT Sciences$876.29 million14.83$-83,990,000.00($1.49)-58.16

Cleveland BioLabs has higher earnings, but lower revenue than EXACT Sciences.

Summary

EXACT Sciences beats Cleveland BioLabs on 8 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and PPD (NASDAQ:PPD) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and PPD, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
PPD001503.00

PPD has a consensus price target of $31.1429, indicating a potential upside of 15.86%. Given PPD's higher probable upside, analysts clearly believe PPD is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 65.5% of PPD shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and PPD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-220.62%-169.32%-102.29%
PPDN/AN/AN/A

Earnings & Valuation

This table compares Cleveland BioLabs and PPD's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million23.01$-2,650,000.00N/AN/A
PPD$4.03 billion2.32$341.61 million$0.9827.43

PPD has higher revenue and earnings than Cleveland BioLabs.

Summary

PPD beats Cleveland BioLabs on 8 of the 10 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Icon (NASDAQ:ICLR) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Icon, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
Icon06502.45

Icon has a consensus price target of $159.1818, indicating a potential downside of 4.63%. Given Icon's higher probable upside, analysts clearly believe Icon is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 82.7% of Icon shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 44.0% of Icon shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Icon's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-220.62%-169.32%-102.29%
Icon13.26%24.20%13.46%

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Icon has a beta of 0.86, indicating that its share price is 14% less volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Icon's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million23.01$-2,650,000.00N/AN/A
Icon$2.81 billion3.19$373.99 million$6.8824.26

Icon has higher revenue and earnings than Cleveland BioLabs.

Summary

Icon beats Cleveland BioLabs on 9 of the 11 factors compared between the two stocks.

Cleveland BioLabs (NASDAQ:CBLI) and Charles River Laboratories Intl. (NYSE:CRL) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Analyst Ratings

This is a summary of recent recommendations for Cleveland BioLabs and Charles River Laboratories Intl., as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cleveland BioLabs0000N/A
Charles River Laboratories Intl.031412.89

Charles River Laboratories Intl. has a consensus price target of $176.8333, indicating a potential downside of 0.05%. Given Charles River Laboratories Intl.'s higher probable upside, analysts clearly believe Charles River Laboratories Intl. is more favorable than Cleveland BioLabs.

Institutional & Insider Ownership

3.6% of Cleveland BioLabs shares are held by institutional investors. Comparatively, 93.1% of Charles River Laboratories Intl. shares are held by institutional investors. 1.9% of Cleveland BioLabs shares are held by insiders. Comparatively, 1.9% of Charles River Laboratories Intl. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Cleveland BioLabs and Charles River Laboratories Intl.'s net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cleveland BioLabs-220.62%-169.32%-102.29%
Charles River Laboratories Intl.9.09%22.69%7.47%

Volatility and Risk

Cleveland BioLabs has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500. Comparatively, Charles River Laboratories Intl. has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cleveland BioLabs and Charles River Laboratories Intl.'s revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cleveland BioLabs$1.11 million23.01$-2,650,000.00N/AN/A
Charles River Laboratories Intl.$2.62 billion3.34$252.02 million$6.7326.29

Charles River Laboratories Intl. has higher revenue and earnings than Cleveland BioLabs.

Summary

Charles River Laboratories Intl. beats Cleveland BioLabs on 11 of the 12 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Iqvia logo
IQV
Iqvia
1.5$141.52flat$27.03 billion$11.09 billion128.66Heavy News Reporting
Incyte logo
INCY
Incyte
1.4$106.47flat$23.14 billion$2.16 billion-60.84Insider Selling
EXACT Sciences logo
EXAS
EXACT Sciences
1.6$86.66flat$12.99 billion$876.29 million-111.10Heavy News Reporting
PPD
PPD
2.1$26.88flat$9.37 billion$4.03 billion27.43
Icon logo
ICLR
Icon
1.6$166.91flat$8.95 billion$2.81 billion24.58
Charles River Laboratories Intl. logo
CRL
Charles River Laboratories Intl.
1.4$176.92flat$8.76 billion$2.62 billion35.60Analyst Upgrade
Heavy News Reporting
Exelixis logo
EXEL
Exelixis
1.8$23.48flat$7.20 billion$967.78 million25.25
PRA Health Sciences logo
PRAH
PRA Health Sciences
1.4$95.05flat$6.06 billion$3.07 billion25.97
Syneos Health logo
SYNH
Syneos Health
1.1$57.53flat$5.99 billion$4.68 billion31.10
Medpace logo
MEDP
Medpace
1.3$93.57flat$3.31 billion$860.97 million32.27Analyst Upgrade
NRC
National Research
0.8$58.35flat$1.47 billion$127.98 million41.68
Precigen logo
PGEN
Precigen
1.7$4.82flat$829.96 million$90.72 million-2.36
Anavex Life Sciences logo
AVXL
Anavex Life Sciences
1.4$4.95flat$290.39 millionN/A-11.00
Luna Innovations logo
LUNA
Luna Innovations
1.7$5.86flat$178.65 million$70.52 million65.11Analyst Downgrade
Pieris Pharmaceuticals logo
PIRS
Pieris Pharmaceuticals
1.4$3.06flat$160.10 million$46.28 million-6.51
BASI
Bioanalytical Systems
1.1$5.24flat$56.93 million$43.62 million-27.58
TENX
Tenax Therapeutics
1.2$0.90flat$8.32 millionN/A0.00
This page was last updated on 7/4/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.